COVID-19 rapid molecular point-of-care testing is effective and cost-beneficial for the acute care of trauma patients

Stolberg-Stolberg ,Josef; Jacob, Elena; Kuehn, Joachim; Hennies, Marc; Hafezi, Wali; Freistuehler, Moritz; Koeppe, Jeanette; Friedrich, Alex W.; Katthagen, J. Christoph; Raschke, Michael J.

Forschungsartikel (Zeitschrift) | Peer reviewed

Zusammenfassung

To evaluate the accuracy and cost benefit of a rapid molecular point-of-care testing (POCT) device detecting COVID-19 within a traumatological emergency department.; Despite continuous withdrawal of COVID-19 restrictions, hospitals will remain particularly vulnerable to local outbreaks which is reflected by a higher institution-specific basic reproduction rate. Patients admitted to the emergency department with unknown COVID-19 infection status due to a- or oligosymptomatic COVID-19 infection put other patients and health care workers at risk, while fast diagnosis and treatment is necessary. Delayed testing results in additional costs to the health care system.; From the 8th of April 2021 until 31st of December 2021, all patients admitted to the emergency department were tested with routine RT-PCR and rapid molecular POCT device (Abbott ID NOW™ COVID-19). COVID-19-related additional costs for patients admitted via shock room or emergency department were calculated based on internal cost allocations.; 1133 rapid molecular tests resulted in a sensitivity of 83.3% (95% CI 35.9-99.6%), specificity of 99.8% (95% CI 99.4-100%), a positive predictive value of 71.4% (95% CI 29-96.3%) and a negative predictive value of 99.9% (95% CI 99.5-100%) as compared to RT-PCR. Without rapid COVID-19 testing, each emergency department and shock room admission with subsequent surgery showed additional direct costs of 2631.25€, without surgery of 729.01€.; Although rapid molecular COVID-19 testing can initially be more expensive than RT-PCR, subsequent cost savings, improved workflows and workforce protection outweigh this effect by far. The data of this study support the use of a rapid molecular POCT device in a traumatological emergency department. - PURPOSE - BACKGROUND - METHODS - RESULTS - CONCLUSION

Details zur Publikation

FachzeitschriftEuropean Journal of Trauma and Emergency Surgery (Eur J Trauma Emerg Surg)
Jahrgang / Bandnr. / Volume49
Ausgabe / Heftnr. / Issue1
Seitenbereich487-493
StatusVeröffentlicht
Veröffentlichungsjahr2023
Sprache, in der die Publikation verfasst istEnglisch
DOI10.1007/s00068-022-02091-x
StichwörterCOVID-19; Rapid molecular point-of care testing; ID NOW; Traumatology; Emergency medicine

Autor*innen der Universität Münster

Freistühler, Moritz
Klinik für Unfall-, Hand- und Wiederherstellungschirurgie
Hafezi, Wali
Institut für Molekulare Virologie
Hennies, Marc Tim
Institut für Molekulare Virologie
Jacob, Janina Elena Marie
Klinik für Unfall-, Hand- und Wiederherstellungschirurgie
Katthagen, Jan Christoph
Klinik für Unfall-, Hand- und Wiederherstellungschirurgie
Köppe, Jeanette
Institut für Biometrie und Klinische Forschung (IBKF)
Kühn, Joachim
Institut für Molekulare Virologie
Raschke, Michael Johannes
Klinik für Unfall-, Hand- und Wiederherstellungschirurgie
Stolberg-Stolberg, Josef
Klinik für Unfall-, Hand- und Wiederherstellungschirurgie